Molecular oncology
A subset of MMR-proficient colon cancers responds to neoadjuvant immunotherapy.
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli
Published: 202510.1002/1878-0261.70178
Abstract
Mismatch repair-proficient (pMMR) colorectal cancers (CRC) have long been considered nonresponsive to immune checkpoint blockade (ICB), in contrast to their mismatch repair-deficient (dMMR) counterparts. Recent evidence indicates that neoadjuvant imm…
Preview only. Read the full abstract at the source